男性与女性乳腺癌诊断后总体死亡率比较
男性患者各分期死亡率均高于女性,临床特征和治疗不足解释了63.3%的额外死亡率,但校正后性别仍是总死亡率的显著因素(调整HR 1.19,95%CI 1.16-1.23)。
要点
- 男性乳腺癌患者总体、3年和5年生存率均低于女性。
- 临床特征和治疗不足解释了男性63.3%的额外死亡率。
- 校正多因素后性别仍与总死亡率独立相关(调整HR 1.19)。
核心结论
- 男性乳腺癌患者诊断后死亡率高于女性,校正临床特征、治疗和医疗可及性后差异仍持续存在。
主要发现
- 男性患者总体生存率45.8%(95%CI 49.5-54.0),3年生存率86.4%(95%CI 85.9-87.0),5年生存率77.6%(95%CI 76.8-78.3)。
- 女性患者总体生存率60.4%(95%CI 58.7-62.0),3年生存率91.7%(95%CI 91.7-91.8),5年生存率86.4%(95%CI 86.4-86.5)。
- 临床特征和治疗不足与男性63.3%的额外死亡率相关,诊断后前3年解释66.0%的额外死亡。
- 校正临床特征、治疗、年龄、种族和医疗可及性后,性别仍与总死亡率(调整HR 1.19,95%CI 1.16-1.23)、3年死亡率(调整HR 1.15,95%CI 1.10-1.21)和5年死亡率(调整HR 1.19,95%CI 1.14-1.23)显著相关。
临床怎么用
- 应关注男性乳腺癌患者治疗不足问题,并探索生物学、治疗依从性和生活方式等额外因素以缩小性别差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Survival differences between male and female patients with breast cancer have been reported, but the underlying factors associated with the disparity have not been fully studied. This understanding is fundamental to developing strategies for cancer treatment and survivorship care. OBJECTIVE: To compare mortality between male and female patients with breast cancer and quantitatively evaluate the factors associated with sex-based disparity in mortality. DESIGN, SETTING, AND PARTICIPANTS: This large, nationwide, registry-based cohort study used the National Cancer Database to identify and obtain data on patients who received a breast cancer diagnosis between January 1, 2004, and December 31, 2014. After exclusions, the final study population comprised 1 816 733 patients. Statistical analyses were conducted from September 1, 2018, to January 15, 2019. MAIN OUTCOMES AND MEASURES: The primary outcome was overall survival. Secondary outcomes were 3-year and 5-year mortality. Mortality differences were evaluated by Kaplan-Meier analysis. The roles of race/ethnicity, clinical characteristics, treatments, and access-to-care factors in the association between sex and mortality were estimated by nested Cox proportional hazards regression models with adjustment for age. RESULTS: In total, 16 025 male (mean [SD] age, 63.3 [13.0] years) and 1 800 708 female (mean [SD] age, 59.9 [13.3] years) patients with breast cancer were included in the study. Compared with female patients, male patients had higher mortality across all stages. For men, the overall survival rate was 45.8% (95% CI, 49.5-54.0; P < .001), the 3-year rate was 86.4% (95% CI, 85.9-87.0; P < .001), and the 5-year rate was 77.6% (95% CI, 76.8-78.3; P < .001). For women, the overall survival rate was 60.4% (95% CI, 58.7-62.0; P < .001), the 3-year rate was 91.7% (95% CI, 91.7-91.8; P < .001), and the 5-year rate was 86.4% (95% CI, 86.4-86.5; P < .001). Overall, clinical characteristics and undertreatments were associated with a 63.3% excess mortality rate for male patients. A higher proportion of excess deaths in men were explained by these factors in the first 3 years after breast cancer diagnosis (66.0%) and in all patients with early-stage cancer (30.5% for stage I and 13.6% for stage II). However, sex remained a significant factor associated with overall mortality (adjusted hazard ratio [HR], 1.19; 95% CI, 1.16-1.23) as well as mortality at 3-year (adjusted HR, 1.15; 95% CI, 1.10-1.21) and 5-year (adjusted HR, 1.19; 95% CI, 1.14-1.23) analyses, even after adjustment for clinical characteristics, treatment factors, age, race/ethnicity, and access to care. CONCLUSIONS AND RELEVANCE: This study found that mortality after cancer diagnosis was higher among male patients with breast cancer compared with their female counterparts. Such disparity appeared to persist after accounting for clinical characteristics, treatment factors, and access to care, suggesting that other factors (particularly additional biological attributes, treatment compliance, and lifestyle factors) should be identified to help in eliminating this disparity.
引用
- Wang F, Shu X, Meszoely I, et al. Overall Mortality After Diagnosis of Breast Cancer in Men vs Women. JAMA Oncol. 2019. PMID: 31536134. doi:10.1001/jamaoncol.2019.2803
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。